SCHEMBL16830101

SCHEMBL16830101

CN(C)C(=O)c1cnco1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA4 P43681 2/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA7 P36544 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
RAB9A P51151 1/20 0.38
F2R P25116 1/20 0.33
FAAH O00519 2/20 0.33
KDM4E B2RXH2 2/20 0.33
GLA P06280 1/20 0.33
CDC7 O00311 1/20 0.33
DBF4 Q9UBU7 1/20 0.33
ALDH1A1 P00352 3/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
ACACB O00763 2/20 0.32
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27892844 0.75 CHRNA4 (0.44) CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL8916525 0.72
SCHEMBL22361539 0.71
Benzene SCHEMBL28325923 0.71 CHRNA4 (0.46) CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL888662 0.71 CHRNA4 (0.39) CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL2625480 0.71 CHRNA4 (0.39) CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL28306983 0.68
SCHEMBL17725298 0.67 ACACB (0.43) CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20570769 0.67
SCHEMBL16027956 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3083627-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PROTOZOAN PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES SUCH AS LEISHMANIASIS Novartis AG (CH) 2016-10-26 EP disclosed
WO-2015095477-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PROTOZOAN PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES SUCH AS LEISHMANIASIS IRM LLC (BM) 2015-06-25 WO disclosed